Results 81 to 90 of about 132,877 (191)

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease [PDF]

, 2009
The events that convert adherent epithelial cells into individual migratory cells that can invade the extracellular matrix are known collectively as epithelial-mesenchymal transition (EMT).
Akitaya, Alkhateeb, Andersson, Barrallo-Gimeno, Bertocchini, Chea, Ciruna, del Barrio, Dixon, Dottori, el Ghouzzi, Favier, Gans, Garcia-Castro, Giehl, Haraguchi, Hervé Acloque, Iwano, Johansson, Kalluri, Katherine Fishwick, Kitajima, Kos, Kwok, Liu, Liu, M. Angela Nieto, Manzanares, Marianne Bronner-Fraser, Martin, Mathieu, Meghan S. Adams, Moreno-Bueno, Nakagawa, Nakaya, Nieto, Peinado, Perea-Gomez, Perez-Pomares, Pijnenborg, Popperl, Sato, Sela-Donenfeld, Sela-Donenfeld, Selleck, Shah, Skromne, Tanimizu, Thiery, Varlet   +49 more
core   +3 more sources

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Sirtuin 7 Promotes Mesenchymal to Epithelial Transition by β-Catenin Redistribution and Stabilization

Frontiers in Oncology, 2020
SIRT7 belongs to the family of “NAD+ dependent deacetylases” called Sirtuins. In the present work we report a novel role of SIRT7 in regulating cellular polarity.
Shashi Kiran, Shashi Kiran, Manjari Kiran, Manjari Kiran, Gayatri Ramakrishna   +4 more
doaj   +1 more source

Chemical regulators of epithelial plasticity reveal a nuclear receptor pathway controlling myofibroblast differentiation [PDF]

, 2016
Plasticity in epithelial tissues relates to processes of embryonic development, tissue fibrosis and cancer progression. Pharmacological modulation of epithelial transitions during disease progression may thus be clinically useful.
Bellomo, C, Bickle, M, Carthy, JM, Gahman, TC, Heldin, A, Heldin, CH, Kardassis, D, Morén, A, Moustakas, A, Shiau, AK, Stöter, M, Vanlandewijck, M, Zerial, M   +12 more
core   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

Does Porphyromonas gingivalis truly inhibit the oral carcinogenesis?

Molecular Oncology, EarlyView.
 
Chen‐xi Li, Zhong‐cheng Gong
wiley   +1 more source

Slug-based epithelial-mesenchymal transition gene signature is associated with prolonged time to recurrence in glioblastoma [PDF]

, 2011
Background We previously identified a precise stage-associated gene expression signature of coordinately expressed genes, including the transcription factor Slug (SNAI2) and other epithelial mesenchymal transition (EMT) markers, present in ...
Darrell J. Yamashiro, Dimitris Anastassiou, Jessica J. Kandel, Peter Canoll, Wei-Yi Cheng   +4 more
core   +1 more source

Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality? [PDF]

, 2016
Systemic Sclerosis (SSc) is a systemic autoimmune disease characterized by progressive fibrosis of skin and multiple internal organs and severe functional and structural microvascular alterations.
Jimenez, Sergio A., Piera-Velazquez, Sonsoles   +1 more
core   +2 more sources